Celator Pharma Revenue, Profits - CPXX Annual Income Statement

Add to My Stocks
$30.24 $0 (0%) CPXX stock closing price Jul 14, 2016 (Closing)

CPXX stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Celator Pharma stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. Like any other income statement, the CPXX income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a YOY revenue decline of 0 when compared to the same period in the past. The Celator Pharma profit and loss statement for 2015 shows a net profit of $-19.31M. Profits for last year was $-16.9M. Apart from this an investor should also check Celator Pharma assets and Celator Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is Jan - Dec20152014201320122011
Celator Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)-----
Celator Pharma Gross Profit
Research & Development Expense11.77M11.89M9.42M4.86M10.6M
Selling General & Admin Expense6.22M5.82M4.99M2.71M4.1M
Income Before Depreciation Depletion Amortization-17.99M-17.71M-14.41M-7.58M-14.7M
Depreciation Depletion Amortization-----
Non Operating Income-0.01M-0.02M-7.49M-0.01M-
Interest Expense1.79M--4.26M-
Celator Pharma Pretax Income
Provision for Income Taxes-0.68M-1.93M-1.41M-1.36M-0.97M
Investment Gains Losses-----
Other Income-----
Income Before Extraordinaries & Disc Operations-19.31M-16.9M-20.84M-10.9M-14.15M
Extraordinary Items & Discontinued Operations-----
Celator Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS33.95M27.42M22M8.41M-
Average Shares used to compute Basic EPS33.95M27.42M22M8.41M-
Income Before Nonrecurring Items-19.32M-16.9M-15.99M-10.91M-
Income from Nonrecurring Items---4.86M--
Celator Pharma Earnings Per Share Basic Net
Celator Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.57-0.62-0.73-1.30-
Preferred Dividends Acc Pd-----
Dividends Common-----
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our Akorn financial analysis

Celator Pharma stock analysis involves checking at least a few of the important things like:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that CPXX stock has a topline or revenue of $- for 2015 as per this Celator Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: Most businesses like Celator Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called the profit and loss statement. Apart from the CPXX income statement, one can check the Celator Pharma historical stock prices to check how the price has moved with time.

Annual Income Statements - Celator Pharmaceuticals Inc Industry Peers

Akorn income statement, Ambit Biosciences income statement, CTI BioPharma income statement, Relypsa income statement